Bristol Myers Squibb CO DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Bristol Myers Squibb announces its 2026 Annual Meeting of Shareholders, highlighting 2025's strong Growth Portfolio sales and strategic pipeline advancements amidst executive compensation and governance proposals.
NYSE
DEFA14A: Bristol-Myers Squibb Outlines Strategy for Sustained Growth and Innovation in Proxy Statement
Bristol-Myers Squibb's proxy statement highlights the company's strategic priorities, including pipeline progress, commercial performance, and commitment to corporate governance, aimed at achieving sustained top-tier growth and maximizing shareholder value.
NYSE
Bristol-Myers Squibb Company announces its 2025 Annual Meeting of Shareholders to be held virtually on May 6, 2025, outlining key voting items including the election of directors and executive compensation.
NYSE
Bristol-Myers Squibb's 2025 proxy statement highlights the company's focus on transformational medicines, operational excellence, and strategic capital allocation to drive sustained growth and shareholder returns.
NYSE
DEFA14A: Bristol-Myers Squibb Outlines Strategy for Sustainable Growth and Innovation in 2024 Proxy Statement
Bristol-Myers Squibb's 2024 proxy statement highlights the company's focus on R&D, business development, ESG initiatives, and sustainable growth, with a target of launching 16 new products by 2030.
NYSE
Bristol-Myers Squibb Company has filed a definitive proxy statement with the SEC.
NYSE
Bristol Myers Squibb's 2024 proxy statement details the company's strategic priorities, governance practices, and executive compensation.